Romulus K. Brazzell
CIK: 0001298079
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
KALA BIO, Inc.
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Oct 22, 2025KALA
KALA BIO, Inc.
Sale(S)Direct46.7K shares at avg. $0.83$39K - Jun 24, 2025KALA
KALA BIO, Inc.
Sale(S)Direct5.3K shares at avg. $4.01$21K - Jun 3, 2025KALA
KALA BIO, Inc.
Sale(S)Direct3.7K shares at avg. $3.74$14K - Jan 6, 2025KALA
KALA BIO, Inc.
Award(A)Direct10.1K shares- - Jan 6, 2025KALA
KALA BIO, Inc.
Sale(S)Direct2.4K shares at avg. $7.63$19K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 22, 2025 | KALA KALA BIO, Inc. | Sale(S) | 46,748 | $0.83 | $38,801 | Direct |
| Jun 24, 2025 | KALA KALA BIO, Inc. | Sale(S) | 5,251 | $4.01 | $21,057 | Direct |
| Jun 3, 2025 | KALA KALA BIO, Inc. | Sale(S) | 3,687 | $3.74 | $13,789 | Direct |
| Jan 6, 2025 | KALA KALA BIO, Inc. | Award(A) | 10,100 | - | $0 | Direct |
| Jan 6, 2025 | KALA KALA BIO, Inc. | Sale(S) | 2,446 | $7.63 | $18,663 | Direct |
1-5 of 5 transactions
About Brazzell Romulus K
Brazzell Romulus K (SEC CIK 0001298079) files insider reports with the SEC as Officer of KALA BIO, Inc. (KALA).
Signal8 holds 5 ownership filings by Brazzell Romulus K, all Form 4s, filed between Jan 7, 2025 and Oct 24, 2025. Those filings report 5 transactions, from Jan 6, 2025 to Oct 22, 2025. Signal8's Form 4 history starts in Sep 2024.
The business address on Brazzell Romulus K's filings is in ARLINGTON, MA.
Recent filings by Brazzell Romulus K
- Oct 22, 2025: Open-market sale of KALA shares (Form 4, code S).
- Jun 24, 2025: Open-market sale of KALA shares (Form 4, code S).
- Jun 3, 2025: Open-market sale of KALA shares (Form 4, code S).
- Jan 6, 2025: Grant or award of KALA shares (Form 4, code A).
- Jan 6, 2025: Open-market sale of KALA shares (Form 4, code S).
Other insiders filing for KALA BIO, Inc. (KALA)
- Purdy Brendan P., Director
- Posen Hillel D., Director
- Minkowitz Avraham, Chief Executive Officer
- Colman Yonatan C., Director
- Berger Chaim D., Director
- Lazar David E., Chief Executive Officer